The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Randomized Controlled Trial of Effect of Prescription of Clozapine Versus Other Second-Generation Antipsychotic Drugs in Resistant Schizophrenia
Open accessAbstract
There is good evidence that clozapine is more efficacious than first-generation antipsychotic drugs in resistant schizophrenia. It is less clear if clozapine is more effective than the other second-generation antipsychotic (SGA) drugs. A noncommercially funded, pragmatic, open, multisite, randomized controlled trial was conducted in the United Kingdom National Health Service (NHS). Participants were 136 people aged 18-65 with DSM-IV schizophrenia and related disorders whose medication was being changed because of poor clinical response to 2 or more previous antipsychotic drugs. Participants were randomly allocated to clozapine or to one of the class of other SGA drugs (risperidone, olanzapine, quetiapine, amisulpride) as selected by the managing clinician. Outcomes were assessed blind to treatment allocation. One-year assessments were carried out in 87% of the sample. The intent to treat comparison showed no statistically significant advantage for commencing clozapine in Quality of Life score (3.63 points; CI: 0.46-7.71; p = .08) but did show an advantage in Positive and Negative Syndrome Scale (PANSS) total score that was statistically significant (-4.93 points; CI: -8.82 to -1.05; p = .013) during follow-up. Clozapine showed a trend toward having fewer total extrapyramidal side effects. At 12 weeks participants who were receiving clozapine reported that their mental health was significantly better compared with those receiving other SGA drugs. In conclusion, in people with schizophrenia with poor treatment response to 2 or more antipsychotic drugs, there is an advantage to commencing clozapine rather than other SGA drugs in terms of symptom improvement over 1 year.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Risperidone versus other atypical antipsychotic medication for schizophrenia
Gilbody, S. M., Bagnall, A., Duggan, L., & Tuunainen, A. (2000) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002306 · Cited by 43
RetractedDiagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. (2013) · Encyclopedia of Social Work · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,519
The Positive and Negative Syndrome Scale (PANSS) for schizophrenia.
Kay, S. R., Fiszbein, A., & Opler, L. A. (1987) · Schizophrenia Bulletin · doi:10.1093/schbul/13.2.261 · Cited by 21,378
(1976) · Medical Entomology and Zoology · Cited by 8,899
Clozapine for the Treatment-Resistant Schizophrenic: A Double-blind Comparison With Chlorpromazine
Kane, J. (1988) · Archives of General Psychiatry · doi:10.1001/archpsyc.1988.01800330013001 · Cited by 4,156
A RATING SCALE FOR EXTRAPYRAMIDAL SIDE EFFECTS
SIMPSON, G. M., B., M., B., G., ANGUS, J. W. S., P., F. R. C., & M., D. P. (1970) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1970.tb02066.x · Cited by 3,264
Lingjærde, O., Ahlfors, U. G., Bech, P., Dencker, S. J., & Elgen, K. (1987) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1987.tb10566.x · Cited by 1,705
The Quality of Life Scale: An Instrument for Rating the Schizophrenic Deficit Syndrome
Heinrichs, D. W., Hanlon, T. E., & Carpenter, W. T. (1984) · Schizophrenia Bulletin · doi:10.1093/schbul/10.3.388 · Cited by 1,688
A depression rating scale for schizophrenics
Addington, D., Addington, J., & Schissel, B. (1990) · Schizophrenia Research · doi:10.1016/0920-9964(90)90005-r · Cited by 1,269
Egger, M., Jüni, P., Bartlett, C., Holenstein, F., & Sterne, J. (2003) · Health Technology Assessment · doi:10.3310/hta7010 · Cited by 1,181
Jones, P. B., Barnes, T. R. E., Davies, L., Dunn, G., Lloyd, H., Hayhurst, K. P., Murray, R. M., Markwick, A., & Lewis, S. W. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.10.1079 · Cited by 1,105
Self-citationHogan, T. P., Awad, A. G., & Eastwood, R. (1983) · Psychological Medicine · doi:10.1017/s0033291700050182 · Cited by 1,028
Chakos, M., Lieberman, J., Hoffman, E., Bradford, D., & Sheitman, B. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.4.518 · Cited by 631
Reliable Estimation of Generalized Linear Mixed Models using Adaptive Quadrature
Rabe-Hesketh, S., Skrondal, A., & Pickles, A. (2002) · The Stata Journal: Promoting communications on statistics and Stata · doi:10.1177/1536867x0200200101 · Cited by 613
A Comparison of Clozapine and Haloperidol in Hospitalized Patients with Refractory Schizophrenia
Rosenheck, R., Cramer, J., Xu, W., Thomas, J., Henderson, W., Frisman, L., Fye, C., & Charney, D. (1997) · New England Journal of Medicine · doi:10.1056/nejm199709183371202 · Cited by 516
Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia
(1994) · American Journal of Psychiatry · doi:10.1176/ajp.151.1.20 · Cited by 388
Measures of quality of life among persons with severe and persistent mental disorders
Lehman, A. F. (1996) · Social Psychiatry and Psychiatric Epidemiology · doi:10.1007/bf00801903 · Cited by 320
Rostami-Hodjegan, A., Amin, A. M., Spencer, E. P., Lennard, M. S., Tucker, G. T., & Flanagan, R. J. (2004) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000106221.36344.4d · Cited by 278
Evaluation of Treatment-Resistant Schizophrenia
Conley, R. R., & Buchanan, R. W. (1997) · Schizophrenia Bulletin · doi:10.1093/schbul/23.4.663 · Cited by 238
Plasma clozapine levels and clinical response for treatment-refractory schizophrenic patients
(1995) · American Journal of Psychiatry · doi:10.1176/ajp.152.2.179 · Cited by 207
Dunn, G., Maracy, M., & Tomenson, B. (2005) · Statistical Methods in Medical Research · doi:10.1191/0962280205sm403oa · Cited by 201
Self-citationVanderZwaag, C. J., McGee, M., McEvoy, J. P., Freudenreich, O., Wilson, W. H., & Cooper, T. B. (1996) · American Journal of Psychiatry · doi:10.1176/ajp.153.12.1579 · Cited by 193
Risperidone versus typical antipsychotic medication for schizophrenia
Hunter, R., Kennedy, E., Song, F., Gadon, L., & Irving, C. B. (2003) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000440 · Cited by 183
A systematic review of atypical antipsychotic drugs in schizophrenia
Bagnall, A. M., Jones, L., Ginnelly, L., Lewis, R., Glanville, J., Gilbody, S., Davies, L., Torgerson, D., & Kleijnen, J. (2003) · Health Technology Assessment · doi:10.3310/hta7130 · Cited by 178
Self-citationClozapine's effectiveness for patients in state hospitals: results from a randomized trial.
Essock, S. M., Hargreaves, W. A., Covell, N. H., & Goethe, J. (1996) · PubMed · Cited by 169
Strengthening clinical effectiveness trials: Equipoise-stratified randomization
Lavori, P. W., Rush, A. J., Wisniewski, S. R., Alpert, J. E., D, M. F. M., Kupfer, D. J., Nierenberg, A. A., Quitkin, F. M., Sackeïm, H. A., Thase, M. E., et al. (2001) · Biological Psychiatry · doi:10.1016/s0006-3223(01)01223-9 · Cited by 153
Dunn, G., Maracy, M. R., Dowrick, C. F., Ayuso‐Mateos, J. L., Dalgard, O. S., Hl, P., Lehtinen, V., Casey, P., Wilkinson, C., Vázquez‐Barquero, J. L., et al. (2003) · The British Journal of Psychiatry · doi:10.1192/bjp.183.4.323 · Cited by 137
Self-citationMedication Self-Management: A preliminary report on an intervention to improve medication compliance
Hayward, P. (1995) · Journal of Mental Health · doi:10.1080/09638239550037343 · Cited by 108
Optimal Dosing of Atypical Antipsychotics in Adults: A Review of the Current Evidence
Citrome, L., & Volavka, J. (2002) · Harvard Review of Psychiatry · doi:10.1080/10673220216279 · Cited by 91
Newer atypical antipsychotic medication versus clozapine for schizophrenia
Tuunainen, A., & Wahlbeck, K. (2000) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000966 · Cited by 84
Risperidone versus clozapine in treatment-resistant schizophrenia: A randomized pilot study
Wahlbeck, K., Cheine, M. V., Tuisku, K., Ahokas, A., Joffe, G., & Rimón, R. (2000) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/s0278-5846(00)00118-4 · Cited by 76
Likelihood Methods for Treatment Noncompliance and Subsequent Nonresponse in Randomized Trials
O’Malley, A. J., & Normand, S. T. (2005) · Biometrics · doi:10.1111/j.1541-0420.2005.040313.x · Cited by 43
Canadian trends in mortality from mental disorders, 1965–1983
Newman, S. C., & Bland, R. C. (1987) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1987.tb02854.x · Cited by 21
Cited by
Tiihonen, J., Lönnqvist, J., Wahlbeck, K., Klaukka, T., Niskanen, L., Tanskanen, A., & Haukka, J. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60742-x · Cited by 1,354
Jones, P. B., Barnes, T. R. E., Davies, L., Dunn, G., Lloyd, H., Hayhurst, K. P., Murray, R. M., Markwick, A., & Lewis, S. W. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.10.1079 · Cited by 1,105
Self-citationThe 2009 Schizophrenia PORT Psychopharmacological Treatment Recommendations and Summary Statements
Buchanan, R. W., Kreyenbuhl, J., Kelly, D. L., Noel, J. M., Boggs, D. L., Fischer, B. A., Himelhoch, S., Fang, B., Peterson, E., Aquino, P. R., et al. (2010) · Schizophrenia Bulletin · doi:10.1093/schbul/sbp116 · Cited by 907
Hasan, A., Falkai, P., Wobrock, T., Lieberman, J., Glenthoj, B., Gattaz, W. F., Thibaut, F., Möller, H.-J., & the Wfsbp Task Force on Treatment Guidelines for Schizophrenia (2012) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2012.696143 · Cited by 637
Barnes, T. R., Drake, R., Paton, C., Cooper, S. J., Deakin, B., Ferrier, I. N., Gregory, C. J., Haddad, P. M., Howes, O. D., Jones, I., et al. (2020) · Journal of Psychopharmacology · doi:10.1177/0269881119889296 · Cited by 606
Self-citation
Metadata
- Authors
- Lewis, S. W., Barnes, T. R. E., Davies, L., Murray, R. M., Dunn, G., Hayhurst, K. P., Markwick, A., Lloyd, H., & Jones, P. B.
- Venue
- Schizophrenia Bulletin
- Publisher
- Oxford University Press (OUP)
- Published
- 2005-10-12
- Volume
- 32
- Issue
- 4
- Pages
- 715-723
- ISSN
- 0586-7614 (ISSN-L)
- 1745-1701
- OpenAlex
- W2127772714
- Cited by
- 422
- References
- 33
- FWCI
- 8.61
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.